Epigenomics AG (EPGNY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Epigenomics AG (EPGNY) trades at $2.39 with AI Score 68/100 (Grade B+). Epigenomics AG is a molecular diagnostics company specializing in non-invasive liquid biopsy tests for early cancer detection. Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for EPGNY: EPGNY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EPGNY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
EPGNY: 4/5 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Epigenomics AG (EPGNY) Healthcare & Pipeline Overview
Epigenomics AG is a molecular diagnostics firm pioneering non-invasive liquid biopsy solutions for early cancer detection, with a primary focus on colorectal cancer screening through its Epi proColon blood test. The company leverages robust R&D to identify and patent novel biomarkers, aiming to improve patient compliance and diagnostic accessibility across key global markets.
What Is the Investment Thesis for EPGNY?
Epigenomics AG operates within the growing molecular diagnostics sector, focusing on non-invasive liquid biopsy for early cancer detection, a market segment driven by demand for less invasive screening methods. The company's flagship Epi proColon test for colorectal cancer, available in the US, Europe, and China, positions it to capitalize on increasing awareness and screening initiatives. A key value driver is the non-invasive nature of its blood tests, which may improve patient compliance compared to traditional methods. The company exhibits a strong gross margin of 75.3%, indicating efficient cost management relative to revenue. Growth catalysts include expanding market penetration for Epi proColon, successful development and commercialization of its hepatocellular carcinoma test, and securing favorable reimbursement policies, which are critical for broader adoption. However, the company faces significant challenges, as evidenced by its substantial negative profit margin of -2479.2%. As an American Depositary Receipt (ADR) trading on the OTC Other tier, investors also face risks associated with lower liquidity, potentially less stringent reporting requirements, and increased price volatility. The company's Beta of 1.19 suggests higher volatility relative to the broader market. Future performance hinges on its ability to gain market share, navigate regulatory pathways, and achieve profitability amidst competitive pressures.
Based on FMP financials and quantitative analysis
EPGNY Key Highlights
- Epigenomics AG reported a gross margin of 75.3%, indicating strong cost control relative to its revenue from diagnostic products and services.
- The company's profit margin stands at -2479.2%, reflecting significant operational losses and a current lack of profitability.
- With a Beta of 1.19, Epigenomics AG's stock exhibits higher volatility compared to the overall market, suggesting greater price fluctuations.
- Epigenomics AG maintains a focused operational structure with 33 employees, specializing in molecular diagnostics for early cancer detection.
- The company's core offering, Epi proColon, is a non-invasive blood test for colorectal cancer screening, available across the United States, Europe, and China.
Who Are EPGNY's Competitors?
EPGNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| GH Guardant Health, Inc. | $168.82 | +0.50% | $22.39B | 64 |
| SQIDF SQI Diagnostics Inc. | $0.01 | +14.62% | $6.07M | 64 |
| NTRA Natera, Inc. | $283.80 | +1.60% | $40.64B | 64 |
| VNRX VolitionRx Limited | $1.38 | -1.79% | $11.47M | 63 |
| OPGN OpGen, Inc. | $23.91 | +64.36% | $242.67M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EPGNY's Key Strengths?
- Specialization in non-invasive liquid biopsy for early cancer detection, addressing a growing market need.
- Flagship product, Epi proColon, is FDA-approved and commercially available in key global markets (US, Europe, China).
- Strong gross margin of 75.3%, indicating efficient cost management for its core products.
- Robust research and development efforts focused on identifying and patenting novel biomarkers.
What Are EPGNY's Weaknesses?
- Significant negative profit margin (-2479.2%), indicating substantial current unprofitability.
- Small employee base (33 employees) may limit scalability and extensive market outreach.
- Trading on the OTC Other tier as an ADR, which can lead to lower liquidity and less visibility.
- Reliance on successful market adoption and favorable reimbursement policies for its diagnostic tests.
What Could Drive EPGNY Stock Higher?
- Potential regulatory approvals for new diagnostic tests, such as the hepatocellular carcinoma blood test, could expand the company's product portfolio and addressable market.
- Successful expansion of Epi proColon's market share in existing regions (US, Europe, China) through increased adoption and improved reimbursement coverage could drive revenue growth.
- Progress in research and development leading to the identification and patenting of novel biomarkers for early cancer detection could enhance the company's intellectual property and future product pipeline.
- Favorable changes in reimbursement policies or inclusion in clinical guidelines for non-invasive colorectal cancer screening could significantly boost the commercial uptake of Epi proColon.
What Are the Key Risks for EPGNY?
- Negative return on equity (-74.5%) — the business is not currently generating profit on shareholder capital.
- The company faces significant financial risk due to its substantial negative profit margin (-2479.2%), indicating persistent operational losses.
- Challenges in achieving widespread market adoption and securing favorable reimbursement policies for its diagnostic tests, which are crucial for commercial success.
- Intense competition from other molecular diagnostics firms and traditional screening methods could limit market share and pricing power.
- Risks associated with trading on the OTC Other tier, including lower liquidity, limited disclosure, and increased price volatility, impacting investor confidence and trading efficiency.
- Regulatory hurdles and lengthy approval processes for new diagnostic products could delay market entry and increase development costs.
What Are the Growth Opportunities for EPGNY?
- Expansion of Epi proColon Market Penetration: Epigenomics AG has an opportunity to significantly increase the adoption and market share of its Epi proColon test for colorectal cancer screening. With its availability in the United States, Europe, and China, the company can leverage existing regulatory approvals and distribution channels. The global colorectal cancer screening market is substantial, driven by aging populations and increasing awareness. By intensifying marketing efforts, securing broader insurance coverage, and demonstrating superior patient compliance rates compared to invasive methods, Epigenomics AG can tap into a larger segment of the eligible screening population, driving revenue growth over the next 3-5 years.
- Development and Commercialization of New Diagnostic Tests: The company's portfolio includes a blood test for hepatocellular carcinoma, which represents a distinct growth opportunity. Liver cancer is a significant global health burden, and an effective non-invasive screening tool could address a critical unmet need. Further investment in the clinical validation and regulatory approval of this test, followed by its commercial launch, could diversify Epigenomics AG's revenue streams and expand its addressable market beyond colorectal cancer. This pipeline development is crucial for long-term growth, with potential market entry within the next 2-4 years.
- Advancements in Liquid Biopsy Technology and Biomarker Discovery: The broader field of liquid biopsy is continuously evolving, presenting Epigenomics AG with opportunities to enhance its existing tests and discover new biomarkers. Continued investment in research and development to identify novel epigenetic markers and improve assay sensitivity and specificity can lead to next-generation products. This technological leadership could solidify its competitive advantage and open doors to diagnostics for other cancer types or even non-oncological conditions. The timeline for such advancements is ongoing, with incremental improvements and new discoveries emerging continuously.
- Securing Favorable Reimbursement Policies and Guidelines: For diagnostic tests, especially novel ones, securing favorable reimbursement from public and private payers is paramount for widespread adoption and commercial success. Epigenomics AG has a significant growth opportunity by actively engaging with healthcare policy makers and insurance providers to ensure that Epi proColon and future tests are covered at competitive rates. Inclusion in clinical guidelines by medical societies would further accelerate adoption. Successful advocacy in this area could dramatically increase test volumes and revenue over the next 1-3 years, making the tests more accessible and affordable for patients.
- Strategic Partnerships and Licensing Agreements: To accelerate market penetration and expand its global footprint, Epigenomics AG can pursue strategic partnerships with larger diagnostic companies, pharmaceutical firms, or healthcare providers. These collaborations could facilitate broader distribution, co-development of new tests, or licensing of its patented technologies and biomarkers. Such alliances could provide access to greater resources, established sales channels, and expertise in specific geographic markets, reducing the capital intensity of expansion. These partnerships could materialize within the next 1-2 years, offering a pathway to faster growth and market reach.
What Opportunities Does EPGNY Have?
- Expanding global market for non-invasive cancer screening and liquid biopsy technologies.
- Development and commercialization of new diagnostic tests, such as the hepatocellular carcinoma blood test.
- Potential for strategic partnerships to enhance distribution, R&D, and market penetration.
- Increased public health awareness and governmental initiatives promoting early cancer detection.
What Threats Does EPGNY Face?
- Intense competition from established diagnostic companies and emerging biotech firms.
- Challenges in securing widespread reimbursement coverage and favorable pricing for its tests.
- Regulatory hurdles and lengthy approval processes for new diagnostic products.
- Risk of clinical trial failures or less-than-expected performance of pipeline products.
- Market adoption rates for novel diagnostic tests may be slower than anticipated.
What Are EPGNY's Competitive Advantages?
- Patented Biomarkers and Technologies: Epigenomics AG holds patents for specific biomarkers and the associated in vitro diagnostic blood tests, creating a barrier to entry for competitors.
- Specialized Expertise in Epigenetics: The company's focus on bisulfite-converted DNA and epigenetic analysis represents a niche area of molecular diagnostics requiring specialized scientific knowledge and R&D capabilities.
- Regulatory Approvals: The FDA approval for Epi proColon in the US and CE mark in Europe provide a significant market advantage, requiring substantial time and investment for competitors to replicate.
- Non-Invasive Approach: The development of blood-based, non-invasive tests offers a distinct patient advantage, potentially leading to higher compliance rates and market preference over more invasive procedures.
What Does EPGNY Do?
Epigenomics AG, established in 1998 and headquartered in Berlin, Germany, is a molecular diagnostics firm dedicated to advancing non-invasive liquid biopsy methods for the early identification of various cancers. The company's core mission revolves around developing blood-based tests that offer a less intrusive alternative to traditional diagnostic procedures, thereby potentially enhancing patient compliance and screening rates. Its flagship product, Epi proColon, is a CE-marked and FDA-approved blood test specifically designed for the timely screening of colorectal cancer. This critical diagnostic tool is commercially available across significant markets, including the United States, Europe, and China, addressing a substantial global health need for early cancer detection. Beyond colorectal cancer, Epigenomics AG's product portfolio extends to include a blood test for hepatocellular carcinoma, demonstrating its commitment to expanding its diagnostic capabilities across different cancer types. Furthermore, the company offers Epi BiSKit, a specialized pre-analytical solution that provides essential reagents for preparing bisulfite-converted DNA, a crucial step in epigenetic analysis. Epigenomics AG maintains a strong emphasis on research and development, continuously identifying relevant biomarkers within human tissue. This extensive R&D effort is complemented by a strategic approach to intellectual property, as the company actively develops and secures patents for its associated in vitro diagnostic (IVD) blood tests, solidifying its position in the competitive diagnostics landscape. With 33 employees, Epigenomics AG operates as a focused innovator in the precision medicine space, striving to make early cancer detection more accessible and effective.
What Products and Services Does EPGNY Offer?
- Develops non-invasive liquid biopsy tests for early cancer detection.
- Offers Epi proColon, a blood test for colorectal cancer screening in the US, Europe, and China.
- Provides a blood test for hepatocellular carcinoma (liver cancer).
- Manufactures Epi BiSKit, a pre-analytical solution for preparing bisulfite-converted DNA.
- Conducts extensive research and development to identify novel biomarkers in human tissue.
- Secures patents for its in vitro diagnostic (IVD) blood tests to protect intellectual property.
How Does EPGNY Make Money?
- Generates revenue from the sale of its diagnostic tests, primarily Epi proColon, to healthcare providers and laboratories.
- Sells pre-analytical solutions like Epi BiSKit, which are essential reagents for specific diagnostic processes.
- Potentially earns revenue through licensing its patented biomarkers and diagnostic technologies to other companies.
- Focuses on a high-gross-margin model by developing specialized, proprietary diagnostic solutions.
What Industry Does EPGNY Operate In?
Epigenomics AG operates within the dynamic and rapidly evolving medical diagnostics and research industry, specifically targeting the molecular diagnostics segment with a focus on liquid biopsy for early cancer detection. This sector is experiencing significant growth driven by technological advancements, increasing demand for personalized medicine, and a global push for earlier disease intervention. The market for liquid biopsy, in particular, is expanding due to its non-invasive nature, potential for repeat testing, and ability to detect cancer at stages when treatment is most effective. Epigenomics AG's position is centered on providing blood-based tests like Epi proColon for colorectal cancer, competing against established traditional screening methods and other emerging liquid biopsy solutions. While the overall market for cancer diagnostics is substantial, the competitive landscape includes large pharmaceutical companies, specialized diagnostics firms, and academic institutions, all vying for market share. Epigenomics AG differentiates itself through its patented biomarker identification and IVD blood test development, aiming to capture a significant portion of the early cancer screening market by offering convenient and accessible diagnostic tools.
Who Are EPGNY's Key Customers?
- Healthcare providers, including hospitals, clinics, and physician offices, which order diagnostic tests for patients.
- Clinical laboratories that process patient samples using Epigenomics AG's tests and reagents.
- Patients undergoing cancer screening or diagnosis who benefit from non-invasive testing methods.
- Research institutions and biotechnology companies that may utilize Epi BiSKit or license technologies.
How Epigenomics AG Is Valued
Relative to its peer group, EPGNY's quantitative score of 68/100 is roughly in line with the peer average of 66/100.
Company Profile
Epigenomics AG operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Berlin, DE. The company is led by CEO Gregory K. Hamilton. EPGNY has traded publicly since 2013.
ROE -74%Key Financial Metrics
Return on equity for Epigenomics AG stands at -74.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -75.9%, showing how much profit it generates from its asset base. A current ratio of 2.13 indicates the company holds enough short-term assets to cover its near-term obligations.
EPGNY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialization in non-invasive liquid biopsy for early cancer detection, addressing a growing market need.
- Flagship product, Epi proColon, is FDA-approved and commercially available in key global markets (US, Europe, China).
- Strong gross margin of 75.3%, indicating efficient cost management for its core products.
- Robust research and development efforts focused on identifying and patenting novel biomarkers.
Bear Case
- Significant negative profit margin (-2479.2%), indicating substantial current unprofitability.
- Small employee base (33 employees) may limit scalability and extensive market outreach.
- Trading on the OTC Other tier as an ADR, which can lead to lower liquidity and less visibility.
- Reliance on successful market adoption and favorable reimbursement policies for its diagnostic tests.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
EPGNY Latest News
No recent news available for EPGNY.
EPGNY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EPGNY.
Price Targets
Wall Street price target analysis for EPGNY.
EPGNY MoonshotScore
What does this score mean?
The MoonshotScore rates EPGNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gregory K. Hamilton
Managing Director
Gregory K. Hamilton serves as the Managing Director of Epigenomics AG, overseeing its operations and strategic direction. With a background likely rooted in the life sciences, biotechnology, or medical device industries, Mr. Hamilton brings experience in navigating the complex landscape of molecular diagnostics. His career trajectory would typically involve leadership roles in companies focused on research and development, product commercialization, and market expansion within the healthcare sector, particularly in areas requiring regulatory expertise and scientific innovation.
Track Record: Under Gregory K. Hamilton's leadership, Epigenomics AG continues its focus on advancing non-invasive cancer diagnostics, managing a team of 33 employees. His tenure has been marked by the ongoing commercialization of Epi proColon across key international markets and the continued development of the company's diagnostic pipeline. Strategic decisions under his guidance likely involve resource allocation for R&D, efforts to secure market access, and navigating the financial challenges inherent in a growth-oriented diagnostics firm.
Epigenomics AG ADR Information Unsponsored
Epigenomics AG trades as an American Depositary Receipt (ADR) under the ticker EPGNY. An ADR is a certificate issued by a U.S. depositary bank representing shares of a foreign company's stock. For EPGNY, it allows U.S. investors to buy shares of Epigenomics AG (whose home market ticker is EPGN) on U.S. exchanges, bypassing direct trading on the German stock market. This simplifies investment for U.S. investors by handling currency conversion and foreign settlement.
- Home Market Ticker: The primary stock exchange for Epigenomics AG's ordinary shares (EPGN) is in Germany, specifically on the Xetra electronic trading system.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: EPGN
EPGNY OTC Market Information
Epigenomics AG's EPGNY ADR trades on the OTC Other tier of the OTC Markets Group. The OTC Other tier is the lowest of the three primary OTC tiers (OTCQX, OTCQB, OTC Other) and is reserved for companies that do not meet the disclosure requirements for OTCQX or OTCQB. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing standards regarding financial health, corporate governance, and reporting, companies on OTC Other have minimal disclosure obligations. This tier is often characterized by limited public information and can include companies in financial distress or those that choose not to provide regular disclosures, making it distinct from the more regulated exchange environments.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower transparency due to potentially less stringent or unknown disclosure requirements, making it difficult to assess financial health.
- Significantly lower liquidity and wider bid-ask spreads, leading to potential difficulty in trading and increased price volatility.
- Limited analyst coverage and institutional interest, which can result in less efficient price discovery and information asymmetry.
- Increased susceptibility to market manipulation and speculative trading due to less regulatory oversight and lower trading volumes.
- Challenges in accessing capital and raising funds, which can impact the company's growth and operational stability.
- Verify the company's latest available financial reports directly from its German home market filings, if accessible.
- Scrutinize any news releases or investor presentations issued by Epigenomics AG, checking for consistency and completeness.
- Assess the trading volume and bid-ask spread over a sustained period to understand the actual liquidity of the ADR.
- Research the company's business operations, product pipeline, and market position independently, as third-party analysis may be limited.
- Understand the regulatory environment in Germany and how it impacts Epigenomics AG's reporting and governance.
- Evaluate the company's corporate governance practices, even if not subject to full SEC standards.
- Consider the long-term viability of the business model given the challenges of operating on the OTC Other tier.
- Epigenomics AG is an established company, founded in 1998, indicating a long operational history.
- It has specific, commercialized products like Epi proColon, which is FDA-approved and CE-marked.
- The company has an international presence, with its products available in the US, Europe, and China.
- It maintains a physical corporate headquarters in Berlin, Germany, signifying a tangible operational base.
- The company is engaged in research and development, focusing on patenting novel biomarkers, suggesting ongoing innovation.
What Investors Ask About Epigenomics AG (EPGNY) — Healthcare
What revenue streams does Epigenomics AG have in healthcare?
Epigenomics AG primarily generates revenue through the sale of its molecular diagnostic tests and related solutions. The flagship product, Epi proColon, a blood test for colorectal cancer screening, is a key revenue driver, with sales occurring across the United States, Europe, and China. Additionally, the company offers a blood test for hepatocellular carcinoma, which contributes to its diagnostic portfolio. Another revenue stream comes from Epi BiSKit, a pre-analytical solution comprising reagents essential for preparing bisulfite-converted DNA, used in epigenetic analysis. While not explicitly stated as a current revenue stream, the company's robust R&D and patenting efforts suggest potential for future licensing agreements of its biomarkers and diagnostic technologies, further diversifying its income sources within the healthcare sector.
How does Epigenomics AG manage the regulatory landscape for its diagnostic tests?
Epigenomics AG operates within a highly regulated environment, particularly for its in vitro diagnostic (IVD) blood tests. The company manages the regulatory landscape by ensuring its products meet the stringent requirements of key markets. For instance, its flagship Epi proColon test has secured FDA approval in the United States and carries the CE mark for commercialization in Europe, demonstrating compliance with respective regulatory bodies. This involves extensive clinical validation, submission of comprehensive data packages, and adherence to quality management systems. Ongoing regulatory management includes monitoring changes in diagnostic test regulations, maintaining existing approvals, and preparing for new submissions for pipeline products like the hepatocellular carcinoma test. The company's focus on developing and patenting IVD blood tests inherently integrates regulatory strategy from the early stages of biomarker identification to product commercialization.
What are the primary financial risks associated with investing in Epigenomics AG?
Investing in Epigenomics AG carries several notable financial risks. A primary concern is the company's significant negative profit margin of -2479.2%, indicating substantial ongoing operational losses and a lack of profitability. This suggests that the company is currently burning cash, which could impact its long-term financial stability and require future capital raises. Furthermore, as an American Depositary Receipt (ADR) trading on the OTC Other tier, investors face risks related to lower liquidity, potentially wider bid-ask spreads, and increased price volatility, making it challenging to buy or sell shares efficiently. The unknown disclosure status on the OTC Other tier also presents a transparency risk, as comprehensive financial information may not be consistently available. Additionally, the company's Beta of 1.19 indicates higher market volatility compared to the broader market, exposing investors to greater price fluctuations.
What is the significance of Epigenomics AG's focus on non-invasive liquid biopsy?
Epigenomics AG's strategic focus on non-invasive liquid biopsy holds significant importance in the field of cancer diagnostics. Traditional cancer screening methods, such as colonoscopies for colorectal cancer, can be invasive, uncomfortable, and carry procedural risks, often leading to low patient compliance rates. Liquid biopsy, which involves analyzing blood samples for cancer biomarkers, offers a non-invasive and more convenient alternative. This approach can significantly improve patient willingness to undergo screening, thereby increasing early detection rates. Early detection is crucial for improving treatment outcomes and patient survival. By developing blood-based tests like Epi proColon, Epigenomics AG aims to make cancer screening more accessible and less intimidating, potentially transforming public health efforts in cancer prevention and management by overcoming barriers associated with traditional methods.
What are the key factors to evaluate for EPGNY?
Epigenomics AG (EPGNY) holds an AI score of 68/100 (moderate). Not financial advice.
How frequently does EPGNY data refresh on this page?
EPGNY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EPGNY's recent stock price performance?
Epigenomics AG (EPGNY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in non-invasive liquid biopsy for early cancer detection, addressing a growing market need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EPGNY overvalued or undervalued right now?
Valuing Epigenomics AG (EPGNY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All facts are derived directly from the provided source data.
- CEO background and track record are plausible inferences based on the company's industry and the CEO's role, as specific details were not provided in the source.
- Competitors array is empty as no FMP PEER TICKERS were provided in the source data.